USC – Technology IP Office and Promising Biotechnologies.
-
Upload
patrick-gilbert -
Category
Documents
-
view
213 -
download
0
Transcript of USC – Technology IP Office and Promising Biotechnologies.
USC – Technology
Introduction
Chad Hardaway, P.E., MBA, JDSenior Licensing AssociateIntellectual Property OfficeUniversity of South CarolinaResearch FoundationLife and Physical Sciences
USC – Technology
New Faculty
New Facilities
Research Focus
Strategic Partnerships
Enhanced Academic Reputation
USC Future Keys to Success
Enhanced Economic Development
USC – Technology
Environmental
Research
BiomedicalSciences
Next Energy
Nanotechnology
Focus Current Research Themes
USC – Technology
Research Centers of Economic Excellence Funded Proposals
• Brain Imaging – $5 million – USC/MUSC
• Regenerative Medicine– $6 million– MUSC/Clemson/USC
• Translational Cancer Therapeutics – $5 million– MUSC/USC
• Drug Discovery in Cancer– $5 million– MUSC/USC
• Vision Science– $4.5 million– MUSC/USC
USC – Technology
NSF Expenditures DataFY02 (latest available)
Institution & Ranking
Total $ Federal Govt.
State & Local Govt.
Industry Institutional Funds
Other
Clemson (87)
134,840
47,174 19,669 12,035 55,444 518
MUSC (90)
132,030
75,803 948 9,939 33,710 11,630
USC (95)
123,108
53,403 5,180 5,050 54,541 4,934
USC – Technology
Intellectual Property Data Activity FY04 FY05 %
Change
Invention Disclosures Received
51 64 25%
Patent Apps. Filed 10 12 20%
Provisional Patent Apps. 20 47 135%
Licenses/Options Signed 10 16 60%
Start-up Companies Formed
2 4 100%
USC – Technology
Intellectual Property Data Activity FY04 FY05 %
Change
Licensing Income Received
$200K $305K 53%
Licensing-related Research Funding
n/a $401K n/a
Total Income from Licensing
$201K $709K 249%
CDA’s 71 120 69%
MTA’s 18 37 105%
USC – Technology
SBIR/STTR Awards
Fiscal Year 2004 2005
Executed Awards
3 9
Executed Awards - $
$
$87,338 $600,484
USC – Technology
USC – Licensing Approaches
Straight Buy-out
Straight Equity
USC has done deals at both
extremes and at all points in between!
$$$$ %%%%
USC – Technology
Promising Biotechnologies
• Featured Technologies
• M3A Novel Antibiotic Compound
• Novel Hypertension Compound
• PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration
• Fluorescent Bioconjugation
• Hernia repair with novel collagen scaffolds
• Additional Technologies
• PAD Inhibitors for treatment of Rheumatoid Arthritis
• Novel Methoxyestradiol Compounds
• Novel Resuscitative Fluid for Trauma Patients
• Cold Sterilization
USC – Technology
M3A Novel Antibiotic Compound
OVERVIEW
Novel AntibioticBroad spectrum activity
Effective against resistant strainsDrug resistance is an ongoing problem
STATUS
Culture process developedInitial efficacy & safety data
US patent issued
DEVELOPMENT NEEDS
Isolate & identify compound(s)Develop production processAdditional efficacy testingPreclinical safety testing
USC – Technology
Novel Hypertension Compound
OVERVIEW
Effective for treatment of cardio conditions and spasmodic asthma
Dual Action – L-type Ca2+ antagonistcAMP PDE inhibitor
Slows rate without blocking antrioventricular conduction
STATUS
In vivo testing on carotid arterial blood pressure
Preliminary in vivo safety dataIn vitro testing on cardio and smooth
muscle effectsUS patent pending
DEVELOPMENT NEEDS
Additional efficacy testingPreclinical safety testingDevelopment to market
Time(min)
0 100 200 300 400 500 600 700
BP
(mm
Hg
)
20
40
60
80
100
120
140
160
180
MAP SBP DBP PP
USC – Technology
PLEOF Copolymer Networks as a Bioresorbable Scaffold for Tissue Regeneration
OVERVIEW
40 M affected by arthritis in US. 1 M patients undergo surgery for osteoarthritis of knee, hip, shoulder, and spine every year.
These PLEOF compounds can be used to repair/ replace damaged bone, cartilage, etc.
STATUS
Preliminary in vitro and in vivo data collectedCan be produced in large quantitiesUS Patent Pending
DEVELOPMENT NEEDS
• Additional efficacy testing• Preclinical safety testing• Short FDA approval route as device• Develop to Market
SpinalFracture
Injection of Composite
USC – Technology
Process for linking nanoparticles Fluorescent signal created with linkage
Wide applications including pharmaceuticals, diagnostics, and
various other nanotech uses
OVERVIEW
DEVELOPMENT STATUS DEVELOPMENT NEED
Lab testing complete Variety of reactions tested
Hundreds of novel dyes madePatent pending
Target market analysisFinancial & business analysis
Validation of target applications
Fluorescent Bioconjugation
+Cu (I) N
NN
N3
prelinkers
biomolecules
"switch"
highly fluorescent linkage
profluorophore
USC – Technology
Hernia repair with novel collagen scaffolds
OVERVIEW
Currently there is no wide acceptance of Engineered soft tissues and no gold standard for repair of ventral hernias. This technology offers a tissue engineered repair system that can rapidly vascularize to repair ventral hernial defects as well as other defects.
STATUS
Repaired over 30 rat ventral hernias Demonstrated the control release technology causes rapid neovascularization Demonstrated differentiated skeletal muscle within the repair site.
DEVELOPMENT NEEDS
•Establish the technology to obtain full thickness muscular repair
•Transfer technology to large animal studies
•Initiate the FDA approval process.
Before
After
USC – Technology
IP Office Contact InformationLisa Rooney, JD, [email protected]
Chad Hardaway, P.E., MBA., JD Senior Licensing Associate803-777-4031 [email protected]
USC Research FoundationIntellectual Property Office901 Sumter Street, Suite 514Columbia, SC 29208
Web Site http://ip.research.sc.edu